[PETDAG] QoQ Cumulative Quarter Result on 31-Mar-2021 [#1]

Stock
[PETDAG] PETRONAS DAGANGAN BHD
Announcement Date
25-May-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Mar-2021 [#1]
Profit Trend
QoQ- -30.75%
YoY- 749.54%
Quarter Report
Latest QR
Upcoming QR
PETDAG's Result
PETDAG's Financial Summary
View:
Show?
Cumulative Result
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Revenue 22,505,326 15,447,970 10,247,308 5,103,318 18,710,947 14,316,139 9,485,661 77.60%
PBT 740,768 540,961 375,421 285,456 386,421 271,030 -17,261 -
Tax -209,537 -147,815 -101,892 -94,292 -114,007 -86,259 -8,766 725.01%
NP 531,231 393,146 273,529 191,164 272,414 184,771 -26,027 -
-
NP to SH 529,754 392,563 273,254 191,113 275,964 186,750 -25,911 -
-
Tax Rate 28.29% 27.32% 27.14% 33.03% 29.50% 31.83% - -
Total Cost 21,974,095 15,054,824 9,973,779 4,912,154 18,438,533 14,131,368 9,511,688 74.49%
-
Net Worth 5,583,211 5,632,884 5,613,015 5,672,622 5,642,818 5,662,687 5,503,735 0.95%
Dividend
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Div 695,417 437,119 238,428 139,083 377,512 208,625 99,345 264.63%
Div Payout % 131.27% 111.35% 87.26% 72.78% 136.80% 111.71% 0.00% -
Equity
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Net Worth 5,583,211 5,632,884 5,613,015 5,672,622 5,642,818 5,662,687 5,503,735 0.95%
NOSH 993,454 993,454 993,454 993,454 993,454 993,454 993,454 0.00%
Ratio Analysis
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
NP Margin 2.36% 2.54% 2.67% 3.75% 1.46% 1.29% -0.27% -
ROE 9.49% 6.97% 4.87% 3.37% 4.89% 3.30% -0.47% -
Per Share
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
RPS 2,265.36 1,554.98 1,031.48 513.69 1,883.42 1,441.05 954.82 77.60%
EPS 53.30 39.50 27.50 19.20 27.80 18.80 -2.60 -
DPS 70.00 44.00 24.00 14.00 38.00 21.00 10.00 264.63%
NAPS 5.62 5.67 5.65 5.71 5.68 5.70 5.54 0.95%
Adjusted Per Share Value based on latest NOSH - 993,454
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
RPS 2,265.36 1,554.98 1,031.48 513.69 1,883.42 1,441.05 954.82 77.60%
EPS 53.30 39.50 27.50 19.20 27.80 18.80 -2.60 -
DPS 70.00 44.00 24.00 14.00 38.00 21.00 10.00 264.63%
NAPS 5.62 5.67 5.65 5.71 5.68 5.70 5.54 0.95%
Price Multiplier on Financial Quarter End Date
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Date 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 -
Price 20.60 19.12 18.60 20.04 21.40 19.74 20.60 -
P/RPS 0.91 1.23 1.80 3.90 1.14 1.37 2.16 -43.71%
P/EPS 38.63 48.39 67.62 104.17 77.04 105.01 -789.82 -
EY 2.59 2.07 1.48 0.96 1.30 0.95 -0.13 -
DY 3.40 2.30 1.29 0.70 1.78 1.06 0.49 262.51%
P/NAPS 3.67 3.37 3.29 3.51 3.77 3.46 3.72 -0.89%
Price Multiplier on Announcement Date
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Date 22/02/22 26/11/21 23/08/21 25/05/21 19/02/21 17/11/20 25/08/20 -
Price 19.98 19.90 18.80 18.82 19.20 19.50 21.22 -
P/RPS 0.88 1.28 1.82 3.66 1.02 1.35 2.22 -45.94%
P/EPS 37.47 50.36 68.35 97.83 69.12 103.73 -813.60 -
EY 2.67 1.99 1.46 1.02 1.45 0.96 -0.12 -
DY 3.50 2.21 1.28 0.74 1.98 1.08 0.47 279.94%
P/NAPS 3.56 3.51 3.33 3.30 3.38 3.42 3.83 -4.74%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment